These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20065511)

  • 1. The effect of nebivolol on atherogenesis in apoE-knockout mice.
    Kus K; Gajda M; Pyka-Fosciak G; Toton-Zuranska J; Pawlowska M; Suski M; Niepsuj A; Nowak B; Wolkow P; Olszanecki R; Jawien J; Korbut R
    J Physiol Pharmacol; 2009 Dec; 60(4):163-5. PubMed ID: 20065511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant deterioration of anti-atherogenic efficacy of nebivolol in a double (apolipoprotein E and endothelial nitric oxide synthase) knockout mouse model of atherosclerosis in comparison to single (apolipoprotein E) knockout model.
    Kus K; Wisniewska A; Toton-Zuranska J; Olszanecki R; Jawien J; Korbut R
    J Physiol Pharmacol; 2014 Dec; 65(6):877-81. PubMed ID: 25554992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice.
    Jawien J; Gajda M; Wołkow P; Zurańska J; Olszanecki R; Korbut R
    J Physiol Pharmacol; 2008 Sep; 59(3):633-9. PubMed ID: 18953103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nebivolol, but not metoprolol, improves endothelial function of the corpus cavernosum in apolipoprotein e-knockout mice.
    Baumhäkel M; Schlimmer N; Büyükafsar K; Arikan O; Böhm M
    J Pharmacol Exp Ther; 2008 Jun; 325(3):818-23. PubMed ID: 18364472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitric oxide mechanisms of nebivolol.
    Maffei A; Lembo G
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of angiotensin-(1-7) peptidomimetic (AVE 0991) and nebivolol on angiotensin I metabolism in aorta of apoE-knockout mice.
    Olszanecki R; Suski M; Gebska A; Toton-Zuranska J; Kus K; Madej J; Bujak-Gizycka B; Jawien J; Korbut R
    J Physiol Pharmacol; 2013 Jun; 64(3):317-20. PubMed ID: 23959728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic dose of nebivolol, a nitric oxide-releasing beta-blocker, reduces atherosclerosis in cholesterol-fed rabbits.
    de Nigris F; Mancini FP; Balestrieri ML; Byrns R; Fiorito C; Williams-Ignarro S; Palagiano A; Crimi E; Ignarro LJ; Napoli C
    Nitric Oxide; 2008 Aug; 19(1):57-63. PubMed ID: 18435936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
    Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
    J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of curcumin on atherosclerosis in apoE/LDLR-double knockout mice.
    Olszanecki R; Jawień J; Gajda M; Mateuszuk L; Gebska A; Korabiowska M; Chłopicki S; Korbut R
    J Physiol Pharmacol; 2005 Dec; 56(4):627-35. PubMed ID: 16391419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nebivolol: a beta blocker with vasodilator properties].
    Waeber B
    Praxis (Bern 1994); 2000 Apr; 89(15):631-3. PubMed ID: 10804847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
    Brodde OE; Philipp T
    Dtsch Med Wochenschr; 2006 Nov; 131(45):2545-50. PubMed ID: 17091442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AVE 0991-angiotensin-(1-7) receptor agonist, inhibits atherogenesis in apoE-knockout mice.
    Toton-Zuranska J; Gajda M; Pyka-Fosciak G; Kus K; Pawlowska M; Niepsuj A; Wolkow P; Olszanecki R; Jawien J; Korbut R
    J Physiol Pharmacol; 2010 Apr; 61(2):181-3. PubMed ID: 20436218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker.
    Prisant LM
    J Clin Pharmacol; 2008 Feb; 48(2):225-39. PubMed ID: 18083889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
    Gupta S; Wright HM
    Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study].
    von Fallois J; Faülhaber HD
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():77-82. PubMed ID: 15700490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of nuclear factor-kappaB attenuates artherosclerosis in apoE/LDLR - double knockout mice.
    Jawień J; Gajda M; Mateuszuk Ł; Olszanecki R; Jakubowski A; Szlachcic A; Korabiowska M; Korbut R
    J Physiol Pharmacol; 2005 Sep; 56(3):483-9. PubMed ID: 16204769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ticlopidine attenuates progression of atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice.
    Jawien J; Csanyi G; Gajda M; Mateuszuk L; Lomnicka M; Korbut R; Chlopicki S
    Eur J Pharmacol; 2007 Feb; 556(1-3):129-35. PubMed ID: 17174298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure.
    Ambrosio G; Flather MD; Böhm M; Cohen-Solal A; Murrone A; Mascagni F; Spinucci G; Conti MG; van Veldhuisen DJ; Tavazzi L; Coats AJ
    Heart; 2011 Feb; 97(3):209-14. PubMed ID: 21138861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-blockers in the management of hypertension: focus on nebivolol.
    Wojciechowski D; Papademetriou V
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):471-9. PubMed ID: 18402537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.